Scientist II, LC-MS Bioanalysis

The Opportunity

We are looking for a Scientist II with expertise in LC-MS/MS-based bioanalysis to support our drug discovery and development pipeline. As a Scientist II specializing in LC-MS/MS, you will independently design, develop, and fit-for-purpose qualify LC-MS/MS methods for analyzing / quantifying drugs (oligonucleotides, biologics, small molecules) in various biological matrices. Your work will be critical in supporting pharmacokinetics (PK), toxicokinetics (TK), pharmacodynamics (PD), and biomarker analysis across preclinical and clinical programs. You will be responsible for method development, troubleshooting, qualification/validation, and execution of studies. This includes oversight of CROs during method transfer, qualification/validation, and sample analysis.

You will collaborate closely with interdisciplinary teams including DMPK, pharmacology, toxicology, clinical development and contribute to the design and implementation of bioanalytical strategies. You will report to the Director of Integrated Bioanalytics. This is a hands-on role that requires onsite laboratory presence at a minimum of 4 days per week.

 

Responsibilities

• Independently design, develop, optimize, and fit for purpose qualify LC-MS/MS methods for the quantitative analysis of various drug modalities (oligonucleotides, biologics and small molecules) in relevant biological matrices (e.g., plasma, serum, tissues), supporting PK, PD, and TK evaluations
• Perform analyte extraction techniques (e.g., immunoprecipitation, SPE, LLE) and sample preparation from complex matrices
• Troubleshoot and maintain instrumentation to ensure robustness, sensitivity, and reproducibility
• Analyze and interpret bioanalytical data, ensuring accuracy and consistency.
• Represent the Bioanalytics function in project team meetings, presenting results and contributing to data-driven decisions
• Collaborate with and manage CROs for method transfer, qualification/validation, sample analysis, and data review; ensure data integrity and timely delivery
• Author and review study plans, method development summaries, validation reports, and regulatory documents (e.g., IND, BLA submissions)
• Contribute to laboratory best practices and support implementation of new workflows and technologies

 

About You

• Ph.D. in Analytical Chemistry, Biochemistry, Pharmaceutical Sciences, or a related field with 2+ years of relevant experience; or M.S. with 5+ years; or B.S. with 7+ years of industry experience in a biotech or pharmaceutical setting
• Hands-on experience with quantitative LC-MS/MS method development and validation in support of biologics, small molecule, peptide, or oligonucleotide bioanalysis
• Proficiency with sample extraction and preparation techniques for biological matrices
• Strong analytical and problem-solving skills, with a focus on assay sensitivity, selectivity, and reproducibility
• Familiarity with regulatory bioanalytical guidelines (e.g., FDA, EMA, ICH M10) and GLP/GCP environments
• Experience with LC-MS/MS instrumentation (e.g., Sciex, Waters, Thermo) and associated software (e.g., Analyst, MassLynx, Xcalibur)
• Demonstrated ability to work cross-functionally and communicate scientific findings effectively
• Ability to interpret bioanalytical data in context of PK/PD is strongly desirable
• Prior experience managing CROs and external assay transfers is preferred
• Prior experience with oligonucleotide drugs is preferred
• Experience supporting IND-enabling studies
• Experience supporting clinical stage programs is a strong plus

 

Compensation & Benefits at insitro

Our target starting salary for successful US-based applicants for this role is $135,000 - $155,000. To determine starting pay, we consider multiple job-related factors including a candidate's skills, education and experience, market demand, business needs, and internal parity. We may also adjust this range in the future based on market data.

This role is eligible for participation in our Annual Performance Bonus Plan (based on company targets by role level and annual company performance) and our Equity Incentive Plan, subject to the terms of those plans and associated policies.

 

In addition, insitro also provides our employees:

• 401(k) plan with employer matching for contributions
• Excellent medical, dental, and vision coverage (insitro pays 100% of premiums for employees on our base plans), as well as mental health and well-being support
• Open, flexible vacation policy
• Paid parental leave
• Quarterly budget for books and online courses for self-development
• Support to occasionally attend professional conferences that are meaningful to your career growth and development
• New hire stipend for home office setup
• Monthly cell phone & internet stipend
• Access to free onsite baristas and cafe with daily lunch and breakfast
• Access to free onsite fitness center
• Commuter benefits

 

insitro is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.

We believe diversity, equity, and inclusion need to be at the foundation of our culture. We work hard to bring together diverse teams–grounded in a wide range of expertise and life experiences–and work even harder to ensure those teams thrive in inclusive, growth-oriented environments supported by equitable company and team practices. All candidates can expect equitable treatment, respect, and fairness throughout the interview process.

#LI-Onsite

About insitro   insitro is a drug discovery and development company using machine learning (ML) and data at scale to decode biology for transformative medicines. At the core of insitro’s approach is the convergence of in-house generated multi-modal cellular data and high-content phenotypic human cohort data. We rely on these data to develop ML-driven, predictive disease models that uncover underlying biologic state and elucidate critical drivers of disease. These powerful models rely on extensive biological and computational infrastructure and allow insitro to advance novel targets and patient biomarkers, design therapeutics and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of insights and therapeutics in neuroscience, oncology and metabolism. Since launching in 2018, insitro has raised over $700 million from top tech, biotech and crossover investors, and from collaborations with pharmaceutical partners. For more information on insitro, please visit www.insitro.com.